ArticleFrontiers in medicine2023

Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial.

Kentaro Oka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.